PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), particularly programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, have significantly improved treatment outcomes for advanced NSCLC, transforming the therapeutic landscape of this disease over the past decade [5].